Fluticasone furoate

Fluticasone furoate is a corticosteroid for the treatment of non-allergic and allergic rhinitis administered by a nasal spray.[2] It is also available as an inhaled corticosteroid to help prevent and control symptoms of asthma. It is derived from cortisol.[3] Unlike fluticasone propionate, which is only approved for children four years and older, fluticasone furoate is approved in children as young as two years of age when used for allergies.[4][5]

For other uses, see Fluticasone.

Fluticasone furoate
Clinical data
AHFS/Drugs.comFDA Professional Drug Information
License data
Pregnancy
category
    Routes of
    administration    		Intranasal, oral inhalation
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Bioavailability0.51% (Intranasal)
    Protein binding91%
    MetabolismIntranasal
    Hepatic (CYP3A4-mediated)
    Elimination half-life15 hours
    ExcretionRenal
    Identifiers
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.158.130
    Chemical and physical data
    FormulaC27H29F3O6S
    Molar mass538.58 g·mol−1
    3D model (JSmol)

    It was approved for medical use in the United States in April 2007, and in the European Union in November 2008.[6][7]

    Brand names

    In the US it is marketed by GlaxoSmithKline for asthma as Arnuity Ellipta and is only available with a prescription.[8] It is marketed over-the-counter for allergic rhinitis as Flonase Sensimist.[9] The Veramyst brand name has been discontinued in the U.S.[4] It is also marketed as Allermist (Japan, アラミスト) and Avamys (Australia, Canada, EU, South Africa, South America, Mexico, Israel, Italy, India and South Korea).

    The combination drug fluticasone furoate/vilanterol, marketed as Breo Ellipta (US, Canada) and Relvar Ellipta (UK),[10][11][12] is approved for use in the United States for long-term maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD).[10] It is also approved for the treatment of asthma.[10]

    See also

    References
    1. "Fluticasone Use During Pregnancy". Drugs.com. 9 January 2019. Retrieved 4 February 2020.
    2. Bruni FM, De Luca G, Venturoli V, Boner AL (2009). "Intranasal corticosteroids and adrenal suppression". Neuroimmunomodulation. 16 (5): 353–62. doi:10.1159/000216193. PMID 19571596.
    3. Kaliner, Michael A. (2011). Rhinitis, An Issue of Immunology and Allergy Clinics - E-Book. Elsevier Health Sciences. ISBN 9781455709328.
    4. "Veramyst". Drugs.com. 21 June 2019. Retrieved 4 February 2020.
    5. "Veramyst- fluticasone furoate spray, metered". DailyMed. 1 March 2010. Retrieved 4 February 2020.
    6. "Drug Approval Package: Veramyst (fluticasone furoate) NDA #022051". U.S. Food and Drug Administration (FDA). 30 August 2010. Retrieved 4 February 2020.
    7. "Avamys EPAR". European Medicines Agency (EMA). Retrieved 5 June 2020.
    8. "Arnuity Ellipta- fluticasone furoate powder". DailyMed. 26 June 2019. Retrieved 4 February 2020.
    9. "Flonase Sensimist Allergy Relief- fluticasone furoate spray, metered". DailyMed. 30 May 2019. Retrieved 4 February 2020.
    10. "Breo Ellipta- fluticasone furoate and vilanterol trifenatate powder". DailyMed. 7 January 2019. Retrieved 4 February 2020.
    11. "Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC)". (emc). 3 January 2019. Retrieved 4 February 2020.
    12. "Relvar Ellipta EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 4 February 2020.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.